Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
8.1
P/B Ratio
1
Industry P/E
--
EV/EBITDA
1.3
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
24,018,900
CFO
$-931.64 Mln
EBITDA
$-1,200.80 Mln
Net Profit
$117.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
| -7.7 | 2.2 | -10.1 | -38.1 | -7.0 | -- | -- |
|
BSE Sensex
| 5.5 | 9.8 | 8.7 | 12.9 | 16.1 | 21.5 | 11.7 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
| -34.3 | -11.7 | -13.8 | -31.5 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
|
17.0 | 408.3 | 4.3 | 53.5 | -- | 12.2 | 8.1 | 1.0 |
| 2.2 | 3.5 | 0.6 | -8.0 | -1,245.8 | -178.5 | -- | 0.0 | |
| 0.3 | 4.2 | 7.5 | -9.0 | -144,731.8 | -0.3 | -- | 0.7 | |
| 118.6 | 11,854.7 | 5,512.6 | 494.7 | 17.0 | 13.8 | 24.2 | 5.5 | |
| 0.6 | 200.2 | 0.0 | -2.4 | -- | 299.5 | -- | 0.0 | |
| 7.5 | 202.1 | 43.0 | -75.0 | -167.4 | -40.8 | -- | 1.4 | |
| 2.2 | 16.6 | 2.7 | -8.2 | -275.0 | -2480.5 | -- | 8.0 | |
| 1.2 | 166.7 | 41.6 | -202.0 | -370.3 | -136.3 | -- | 1.6 | |
| 0.5 | 17.0 | 0.0 | 2,778.9 | -268,238.4 | 33.7 | 4.7 | 1.0 | |
| 1.0 | 3.9 | 0.0 | -3.3 | -- | -109.8 | -- | 1.2 |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and... LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. Address: 6 Tide Street, Boston, MA, United States, 02210 Read more
Founder, Senior Advisor & Board Observer
Ms. Daphne Zohar
Founder, Senior Advisor & Board Observer
Ms. Daphne Zohar
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PureTech Health PLC (PRTC) stood at $ 603 Mln as on 31-Dec-24
The share price of PureTech Health PLC (PRTC) is $17.04 (NASDAQ) as of 15-May-2025 10:41 EDT. PureTech Health PLC (PRTC) has given a return of -7.02% in the last 3 years.
PureTech Health PLC (PRTC) has a market capitalisation of $ 408 Mln as on 14-May-2025. As per Value Research classification, it is a company.
The P/E ratio of PureTech Health PLC (PRTC) is 8.10 times as on 14-May-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PureTech Health PLC (PRTC) and enter the required number of quantities and click on buy to purchase the shares of PureTech Health PLC (PRTC).
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. Address: 6 Tide Street, Boston, MA, United States, 02210
The CEO & director of Ms. Daphne Zohar. is PureTech Health PLC (PRTC), and CFO & Sr. VP is Ms. Daphne Zohar.
There is no promoter pledging in PureTech Health PLC (PRTC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
22
|
|
|
20
|
|
|
18
|
|
|
2
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,172
|
| PureTech Health PLC (PRTC) | Ratios |
|---|---|
|
Return on equity(%)
|
12.18
|
|
Operating margin(%)
|
783.57
|
|
Net Margin(%)
|
1240.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PureTech Health PLC (PRTC) was No Profit.
$0.32
(
